Relevant bibliographies by topics / Intravenous Immunoglobulin

Academic literature on the topic 'Intravenous Immunoglobulin'

Author: Grafiati
Published: 4 June 2021
Last updated: 21 February 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Intravenous Immunoglobulin.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Intravenous Immunoglobulin"

1

Besa, Emmanuel C., and Barbara A. Neilan. "Intravenous immunoglobulin." Postgraduate Medicine 86, no. 6 (November 1989): 189–95. http://dx.doi.org/10.1080/00325481.1989.11704485.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

MD, Y. G. "Intravenous immunoglobulin." Neurology 42, no. 10 (October 1, 1992): 2053. http://dx.doi.org/10.1212/wnl.42.10.2053-a.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Wedgwood, Ralph J. "Intravenous immunoglobulin." Clinical Immunology and Immunopathology 40, no. 1 (July 1986): 147–50. http://dx.doi.org/10.1016/0090-1229(86)90079-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Cowden, Jessica, and Sarah K. Parker. "Intravenous Immunoglobulin." Pediatric Infectious Disease Journal 25, no. 7 (July 2006): 641–42. http://dx.doi.org/10.1097/01.inf.0000223517.98486.2f.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Chapel, H. "Intravenous immunoglobulin therapy." QJM 89, no. 9 (September 1, 1996): 641–44. http://dx.doi.org/10.1093/qjmed/89.9.641.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Gordon, David S. "Intravenous immunoglobulin therapy." American Journal of Medicine 83, no. 4 (October 1987): 52–56. http://dx.doi.org/10.1016/0002-9343(87)90551-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Phillips, Rebecca. "Intravenous Immunoglobulin Administration." Biology of Blood and Marrow Transplantation 20, no. 2 (February 2014): S306—S307. http://dx.doi.org/10.1016/j.bbmt.2013.12.531.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Dhar, Sandipan. "Intravenous immunoglobulin in dermatology." Indian Journal of Dermatology 54, no. 1 (2009): 77. http://dx.doi.org/10.4103/0019-5154.48996.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Raghavendra, S., Javeria Nooraine, and RajeshB Iyer. "Intravenous immunoglobulin induced meningoencephalitis." Neurology India 62, no. 1 (2014): 98. http://dx.doi.org/10.4103/0028-3886.128354.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Foster, P. R., A. G. Welch, B. Cuthbertson, R. J. Perry, and R. V. McIntosh. "Immunoglobulin for intravenous use." Transfusion Medicine 7, no. 1 (March 1997): 67–69. http://dx.doi.org/10.1046/j.1365-3148.1997.d01-83.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Intravenous Immunoglobulin"

1

Das, Mrinmoy. "The regulatory effects of circulating normal immunoglobulins on autophagy and Th17 response." Thesis, Paris 6, 2017. http://www.theses.fr/2017PA066153/document.

Full text
Abstract:
Les immunoglobulines circulantes jouent un rôle critique dans l’homéostasie immune en modulant les fonctions des cellules du système immunitaire. Au cours de ma thèse, j’ai exploré les effets régulateurs des immunoglobulines G thérapeutiques (IVIG) et des immunoglobulines A monomériques circulantes (mIgA) sur l’autophagie et les réponses Th17 respectivement. Les IVIg sont une préparation thérapeutique d’IgG normales poolées. Elles ont utilisées comme agent anti-inflammatoire dans le traitement de maladies auto-immunes et inflammatoires variées. Cependant, les mécanismes ne sont pas complètement élucidés et plusieurs mécanismes mutuels et non exclusifs ont été proposés. L’autophagie est un important processus biologique impliquant la dégradation lysosomale des composants cellulaires endommagés et des protéines mal repliées. Il y a plusieurs preuves montrant l’implication de l’autophagie dans les maladies auto-immunes et auto-inflammatoires incluant la découverte de polymorphismes dans des gènes liés à l’autophagie. J’ai montré que l’induction de l’autophagie par les IVIG représente un nouveau mécanisme d’action permettant leur effet thérapeutique dans les maladies auto-immunes et inflammatoires. Les Th17 représentent une cible attractive pour traiter plusieurs maladies inflammatoires et auto-immunes. Malgré le fait qu’elles sont le deuxième anticorps le plus abondant dans la circulation, la function immunorégulatrice des IgA n’est relativement pas explorée. J’ai montré que les IgA monomériques (mIgA) inhibent la différentiation et l’amplification des cellules Th17 humaines et la production de leur cytokine effectrice IL-17A
Circulating immunoglobulins play a critical role in the immune homeostasis by modulating the functions of immune cells. In my thesis, I investigated the regulatory effects of therapeutic immunoglobulin G (IVIG) and circulating monomeric immunoglobulin A (mIgA) on autophagy and human Th17 response respectively. IVIG is a therapeutic preparation of pooled normal IgG. It is used as an anti-inflammatory agent in the treatment of a wide variety of autoimmune and inflammatory diseases. However, the mechanisms are not yet fully elucidated and several mutually non-exclusive mechanisms have been proposed. Autophagy is an important biological process involving lysosomal degradation of damaged cellular components and misfolded proteins. There are several evidences that support the involvement of autophagy in autoimmune and auto- inflammatory disorders including the discovery of polymorphisms in autophagy-related genes. I show that induction of autophagy by IVIG represents a novel mechanism of action in achieving therapeutic effect in autoimmune and inflammatory diseases. Th17 cells represent an attractive target to treat several inflammatory and autoimmune diseases. Despite being second most abundant antibody in the circulation, the immunoregulatory function of IgA is relatively unexplored. I have shown that monomeric IgA (mIgA) inhibits differentiation and amplification of human Th17 cells and the production of their effector cytokine IL-17A
APA, Harvard, Vancouver, ISO, and other styles
2

Bilal, Jawad, Irbaz B. Riaz, Jennifer L. Hill, and Tirdad T. Zangeneh. "Intravenous Immunoglobulin-Induced Pulmonary Embolism: It Is Time to Act!" LIPPINCOTT WILLIAMS & WILKINS, 2016. http://hdl.handle.net/10150/620829.

Full text
Abstract:
Pulmonary embolism (PE) is a common clinical problem affecting 600,000 patients per year in the United States. Although the diagnosis can be easily confirmed by imaging techniques, such as computed tomographic angiography of the chest, the identification of underlying mechanism leading to PE is important for appropriate duration of anticoagulation, and prevention of subsequent episodes. The differential diagnosis of underlying mechanism is broad and must include careful review of medication history. Drug-related thromboembolic disease can be easily missed and may have catastrophic consequences. The identification of the culprit drug is important for prevention of subsequent episodes and choosing appropriate duration of anticoagulation. We report a case of a middle-aged man who developed PE after administration of intravenous immunoglobulin.
APA, Harvard, Vancouver, ISO, and other styles
3

Pain, Elisabeth. "Investigation of the immunomodulatory properties of intravenous immunoglobulin G (IVIg)." Thesis, University of Bristol, 2002. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.251131.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Lam, Shang Leen Clifford. "Plasma procurement and clinical evaluation of an intravenous immunoglobulin preparation." Thesis, University of Edinburgh, 1987. http://hdl.handle.net/1842/19028.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Taylor, Rosemary. "Clinical Practice Guidelines for Home Management of Intravenous Immunoglobulin Therapy." ScholarWorks, 2019. https://scholarworks.waldenu.edu/dissertations/7342.

Full text
Abstract:
The infusion of intravenous immunoglobulin therapy in the home setting requires a critical nursing assessment and interventions aimed at managing and preventing the escalation of adverse events. Some patients experience side effects that necessitate a rapid response by field nurses, requiring standing orders for nursing administration and the availability of essential medications to alleviate symptoms in the patient's home. The clinical practice issue was that the home health agency did not have a uniform clinical practice nursing guideline to assist field nurses in providing rapid responses for managing infusion-related reactions. The purpose of this project was to develop an evidence-based clinical practice guideline using standing orders for the comprehensive management of immunoglobulin side effects in the patient's home. The practice-focused question centered on whether the use of a nursing practice guideline based on interprofessional collaboration could manage the side effects of patients in the home by decreasing the use of emergent care and improved quality of care for those patients susceptible to significant side effects. An interdisciplinary expert panel experience in IVIG l used Newman's system theory and the reach, effectiveness, adoption, implementation, maintenance framework for interprofessional collaboration in developing a clinical nursing guideline with a standing order for rating side effects. Panelists used the appraisal of guidelines, research, and evaluation II tool to appraise the evidence for the guideline. The use of clinical guideline with standing orders to address the needs of patients in the home setting may lead to positive social change by enabling more rapid management of symptoms, more effective care in the home, and improved patient outcomes
APA, Harvard, Vancouver, ISO, and other styles
6

Lin, Hsin Hsin. "Mechanisms of Intravenous Immunoglobulin in the Treatment of Experimental Autoimmune Neuritis." University of Sydney, 2007. http://hdl.handle.net/2123/1696.

Full text
Abstract:
PhD
The aims of this study were to test the efficacy of immunoglobulin and its Fab and Fc fragment in the treatment of experimental autoimmune neuritis (EAN) in Lewis rats, to investigate which portion of immunoglobulin is operative in the effect of IVIg, and to clarify the possible mechanisms by which immunoglobulin exerts its action in the treatment of rats EAN. EAN was induced by immunization with whole bovine peripheral nerve myelin. The immunized rats were randomized into groups, assessed clinically, electrophysiologically, and histologically, and intravenously injected with normal saline, albumin, human IVIg preparation, purified Fab or Fc fragments. The treatment efficacy was compared between normal saline and albumin groups, albumin and IVIg groups, albumin and Fab groups, albumin and Fc groups, Fab and Fc groups, Fab and IVIg groups, and Fc and IVIg groups. Methods of myelin isolation, antibody purification, and Western blot techniques were also applied. The results revealed that treatment with Fc fragment and IVIg at the onset of signs of disease effectively prevented further progression of disease, shortened disease duration, and facilitating recovery from illness as shown in clinical, electrophysiological and histological parameters. In the study which the efficacy of albumin and IVIg was compared, 5 out of 17 rats (29%) in the albumin group and 12 out of 17 (71%) in the IVIg group completely recovered from the clinical disease by day 30. The animals receiving IVIg treatment exhibited lower clinical scores, less prolongation of S wave latencies, better maintained S wave amplitudes, less reduction of distal motor NCVs, better maintained distal and proximal CMAP amplitudes, and lower histological grades. In the study which the efficacy of albumin, Fab fragment, Fc fragment, and IVIg was compared, 0 out of 8 (0%) in the albumin group, 1 out of 8 (13%) in the Fab group, 4 out of 8 (50%) in the Fc group, and 6 out of 9 (67%) rats in the IgG group completely recovered from the clinical disease by day 30. The animals receiving Fc fragment and IVIg treatment exhibited lower clinical scores, less prominent weight loss, less prolongation of S wave latencies, better maintained S wave amplitudes, less reduction of distal motor NCVs, better maintained distal and proximal CMAP amplitudes, and lower histological grades.
APA, Harvard, Vancouver, ISO, and other styles
7

Lin, Hsin Hsin. "Mechanisms of Intravenous Immunoglobulin in the Treatment of Experimental Autoimmune Neuritis." Thesis, The University of Sydney, 2006. http://hdl.handle.net/2123/1696.

Full text
Abstract:
The aims of this study were to test the efficacy of immunoglobulin and its Fab and Fc fragment in the treatment of experimental autoimmune neuritis (EAN) in Lewis rats, to investigate which portion of immunoglobulin is operative in the effect of IVIg, and to clarify the possible mechanisms by which immunoglobulin exerts its action in the treatment of rats EAN. EAN was induced by immunization with whole bovine peripheral nerve myelin. The immunized rats were randomized into groups, assessed clinically, electrophysiologically, and histologically, and intravenously injected with normal saline, albumin, human IVIg preparation, purified Fab or Fc fragments. The treatment efficacy was compared between normal saline and albumin groups, albumin and IVIg groups, albumin and Fab groups, albumin and Fc groups, Fab and Fc groups, Fab and IVIg groups, and Fc and IVIg groups. Methods of myelin isolation, antibody purification, and Western blot techniques were also applied. The results revealed that treatment with Fc fragment and IVIg at the onset of signs of disease effectively prevented further progression of disease, shortened disease duration, and facilitating recovery from illness as shown in clinical, electrophysiological and histological parameters. In the study which the efficacy of albumin and IVIg was compared, 5 out of 17 rats (29%) in the albumin group and 12 out of 17 (71%) in the IVIg group completely recovered from the clinical disease by day 30. The animals receiving IVIg treatment exhibited lower clinical scores, less prolongation of S wave latencies, better maintained S wave amplitudes, less reduction of distal motor NCVs, better maintained distal and proximal CMAP amplitudes, and lower histological grades. In the study which the efficacy of albumin, Fab fragment, Fc fragment, and IVIg was compared, 0 out of 8 (0%) in the albumin group, 1 out of 8 (13%) in the Fab group, 4 out of 8 (50%) in the Fc group, and 6 out of 9 (67%) rats in the IgG group completely recovered from the clinical disease by day 30. The animals receiving Fc fragment and IVIg treatment exhibited lower clinical scores, less prominent weight loss, less prolongation of S wave latencies, better maintained S wave amplitudes, less reduction of distal motor NCVs, better maintained distal and proximal CMAP amplitudes, and lower histological grades.
APA, Harvard, Vancouver, ISO, and other styles
8

Miyakoshi, Chisato. "Heart Rate, Responsiveness to Intravenous Immunoglobulin, and Coronary Artery Aneurysms in Kawasaki Disease." Kyoto University, 2019. http://hdl.handle.net/2433/236617.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Yu, Xiaojie. "Immunomodulatory properties of IgG glycosylation and the anti-inflammatory mechanism of intravenous immunoglobulin." Thesis, University of Oxford, 2013. http://ora.ox.ac.uk/objects/uuid:140048b3-7cf4-4a30-932b-59c3e1d20272.

Full text
Abstract:
The IgG Fc domain mediates a range of antibody effector functions, including antibody dependent cell-mediated cytotoxicity (ADCC), complement activation, phagocytosis, and the recently emerged general anti-inflammatory effect of immunoglobulin therapy (IVIg). The conserved N-glycan attached to Fc N297 maintains the Fc structural integrity for the effector functions, while its glycoform is known to modulate the affinity for the Fc γ-receptors (FcγRs), complement, and the C-type lectin DC-SIGN. IgG Fc exhibits protein-directed glycosylation characterized by a series of biantennary complex type glycoforms, with a small population of sialylated species. The sialylated Fc has been proposed to bind DC-SIGN and initiate an anti-inflammatory signalling pathway. The restricted Fc glycan processing is partially attributed to the hydrophobic interaction between Fc glycan and the hydrophobic Fc protein backbone. Mutations within the hydrophobic Fc protein-glycan interface dramatically increases Fc glycan processing, while concomitantly decreases Fc affinity for the FcγRs. However, it is unclear whether this disrupted Fc-FcγR interaction was due to the increased terminal glycan processing, or the perturbed Fc protein-glycan interface. Here, the integrity of the Fc protein-glycan interface was demonstrated to be important in maintaining the productive Fc-FcγR interaction independently of glycoform. This glycoform-independent effect was exploited to generate novel inhibitory Fc variants. In addition, the interaction between sialylated IgG and the putative IVIg receptor DC-SIGN was re-evaluated. Analysis shows that IVIg binds DC-SIGN in a glycan-independent, Fab-mediated manner. Furthermore, the effect of IVIg sialylation on human antigen presenting cells was examined; evidence presented here indicate that IVIg deglycosylation, not desialylation, has an anti-inflammatory effect on human dendritic cells (DCs). These data suggest the need for a general re-evaluation of the current mechanistic model of anti-inflammatory IVIg.
APA, Harvard, Vancouver, ISO, and other styles
10

Klaesson, Sven. "Immune modulatory effects of intravenous immunoglobulin in vitro and after allogeneic bone marrow transplantation /." Stockholm, 1997. http://diss.kib.ki.se/1997/91-628-2636-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Intravenous Immunoglobulin"

1

Stephen, Jolles, ed. Intravenous immunoglobulin in dermatology. London: Martin Dunitz, 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Lazarus, Alan H. Immunoglobulin therapy. Bethesda, Md: AABB Press, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Beratan, Marian E. Intravenous immunoglobulin: Prevention and treatment of disease : January 1986 through April 1990 : 888 citations. Bethesda, Md: U.S. Dept. of Health and Human Services, Public Health Service, National Institutes of Health, National Library of Medicine, Reference Section ; Washington, D.C. : Sold by the Supt. of Docs., U.S. G.P.O., 1990.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

International Symposium on IVIG (4th 1996 Interlaken, Switzerland). Advances in intravenous immunoglobulin research and therapy: Proceedings from Interlaken's Fourth International Symposium on IVIG, 11-13 June, 1996. New York: Parthenon Pub. Group, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

International Society of Hematology. Congress. Immunomodulation by intravenous immunoglobulin: The proceedings of a symposium held at the 24th Congress of the International Society of Haematology, London, UK, August 1992, combined with the proceedings of an international symposium held in Mar del Plata, Argentina, October 1992. Carnforth, Lancs, UK: Parthenon Pub. Group, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

1953-, Lee Martin L., and Strand Vibeke, eds. Intravenous immunoglobulins in clinical practice. New York: Dekker, 1997.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Delire, Marcel. Immunoglobulins: Rationale for the clinical use of polyvalent intravenous immunoglobulins. Petersfield, UK: Wrightson Biomedical Pub., 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

C, Dalakas Marinos, and Späth Peter C, eds. Intravenous immunoglobulins in the third millennium. Boca Raton: Parthenon Pub. Group, 2004.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Senate, United States Congress. A bill to amend title XVIII of the Social Security Act to improve access of Medicare beneficiaries to intravenous immune globulins. Washington, D.C: U.S. G.P.O., 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

United States. Congress. House. A bill to amend title XVIII of the Social Security Act to improve access of Medicare beneficiaries to immune globulins. [Washington, D.C.?]: [United States Government Printing Office], 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Intravenous Immunoglobulin"

1

Newland, A. C., and P. A. Veys. "Intravenous Immunoglobulin." In Immunotherapy of Disease, 21–42. Dordrecht: Springer Netherlands, 1989. http://dx.doi.org/10.1007/978-94-009-1844-3_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Phillips, Derrick. "Intravenous Immunoglobulin." In Handbook of Systemic Drug Treatment in Dermatology, 164–69. 3rd ed. London: CRC Press, 2022. http://dx.doi.org/10.1201/9781003016786-24.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Banik, Biswajit, and Niraj Arora. "Intravenous Immunoglobulin." In Procedures and Protocols in the Neurocritical Care Unit, 601–16. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-90225-4_28.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Borkar, Durga S., and Nicholas J. Butler. "Interferons and Intravenous Immunoglobulin." In Treatment of Non-infectious Uveitis, 113–29. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-22827-9_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Jayne, David. "Intravenous immunoglobulin as immuno-modifying treatment." In Disease-modifying Therapy in Vasculitides, 81–111. Basel: Birkhäuser Basel, 2001. http://dx.doi.org/10.1007/978-3-0348-8235-4_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Bar-Dayan, Y., S. V. Kaveri, Y. Bar-Dayan, A. Pashov, Y. Shoenfeld, and M. D. Kazatchkine. "Anti-Inflammatory Effects of Intravenous Immunoglobulin." In Symposium in Immunology VIII, 171–84. Berlin, Heidelberg: Springer Berlin Heidelberg, 1999. http://dx.doi.org/10.1007/978-3-642-59947-7_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Dalakas, Marinos C. "Use of Intravenous Immunoglobulin in Neurology." In Antibody Therapy, 101–9. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-68038-5_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Hoffmann, Jochen H. O., and Alexander H. Enk. "Use of Intravenous Immunoglobulin in Dermatology." In Antibody Therapy, 111–18. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-68038-5_9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Richter, Christiane, Armin Schnabel, Elena Csernok, Eva Reinhold-Keller, and Wolfgang L. Gross. "Treatment of Wegener’s Granulomatosis with Intravenous Immunoglobulin." In Advances in Experimental Medicine and Biology, 487–89. Boston, MA: Springer US, 1993. http://dx.doi.org/10.1007/978-1-4757-9182-2_88.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Amber, Kyle T., Jessica Shiu, Katherine Ferris, and Sergei A. Grando. "Role of Intravenous Immunoglobulin in Dermatologic Disorders." In Biologic and Systemic Agents in Dermatology, 401–23. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-66884-0_39.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Intravenous Immunoglobulin"

1

Decarout, L., M. Hermet, and M. Zenut. "DI-025 Intravenous immunoglobulin induced agranulocytosis." In 22nd EAHP Congress 22–24 March 2017 Cannes, France. British Medical Journal Publishing Group, 2017. http://dx.doi.org/10.1136/ejhpharm-2017-000640.272.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Balbir-Gurman, A., D. Schapira, B. Smolin, E. Volfovitz, and AM Nahir. "AB0095 Intravenous immunoglobulin in limited polyarteritis nodosa." In Annual European Congress of Rheumatology, Annals of the rheumatic diseases ARD July 2001. BMJ Publishing Group Ltd and European League Against Rheumatism, 2001. http://dx.doi.org/10.1136/annrheumdis-2001.202.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Domínguez Bachiller, M., MI Barcia Martin, AM Martin de Rosales, and M. Pérez Encinas. "5PSQ-044 Aseptic meningitis induced by intravenous immunoglobulin." In 24th EAHP Congress, 27th–29th March 2019, Barcelona, Spain. British Medical Journal Publishing Group, 2019. http://dx.doi.org/10.1136/ejhpharm-2019-eahpconf.477.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Machado, S., M. Silva, M. Pereira, A. Moleiro, and P. Sádio. "4CPS-261 Use of intravenous immunoglobulin: by the book?" In 25th Anniversary EAHP Congress, Hospital Pharmacy 5.0 – the future of patient care, 23–28 March 2021. British Medical Journal Publishing Group, 2021. http://dx.doi.org/10.1136/ejhpharm-2021-eahpconf.93.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Bezerra, Lia B. M., Letícia K. Dourado, Thiago O. Mencdonça, Telma Antunes, and Carmen S. V. Barbas. "Immunoglobulin G Deficiency Associated With Wegener Granulomatosis: Patients Clinical Characteristics And Replacement Therapy With Intravenous Immunoglobulin." In American Thoracic Society 2010 International Conference, May 14-19, 2010 • New Orleans. American Thoracic Society, 2010. http://dx.doi.org/10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a2990.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Airoldi Rodrigues, Lívia, Jean Marcos de Souza, Aldrei Costa Araújo, Giovanna Paliares Monteiro, and Carolina Carotenuto Ramos. "INTRAVENOUS IMMUNOGLOBULIN FOR PYODERMA GANGRENOUSUM ASSOCIATED WITH CUTANEOUS MYCOBACTERIAL INFECTION." In Congresso Brasileiro de Reumatologia 2020. Sociedade Brasileira de Reumatologia, 2021. http://dx.doi.org/10.47660/cbr.2020.17364.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

García, ME Cárdaba, A. De Frutos Soto, M. Izquierdo Navaro, J. Varela González-Aller, and MT Sánchez. "CP-038 Use and economic impact of intravenous immunoglobulin at a university hospital." In 22nd EAHP Congress 22–24 March 2017 Cannes, France. British Medical Journal Publishing Group, 2017. http://dx.doi.org/10.1136/ejhpharm-2017-000640.37.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Santos Hoff, Leonardo, Fernando Henrique Carlos de Souza, Renata Miossi, and Samuel Katsuyuki Shinjo. "Long-term effects of early pulse intravenous methylprednisolone or intravenous immunoglobulin in adult patients with dermatomyositis and polymyositis: a large retrospective." In SBR 2021 Congresso Brasileiro de Reumatologia. Sociedade Brasileiro de Reumatologia, 2021. http://dx.doi.org/10.47660/cbr.2021.1803.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Kamali, S., A. Gül, M. Inanç, A. Çefle, M. Sayarlioglu, O. Aral, and M. Koniçe. "AB0212 Experience with intravenous immunoglobulin therapy in twenty patients with different autoimmune rheumatic diseases." In Annual European Congress of Rheumatology, Annals of the rheumatic diseases ARD July 2001. BMJ Publishing Group Ltd and European League Against Rheumatism, 2001. http://dx.doi.org/10.1136/annrheumdis-2001.733.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Badenhorst, P. N., H. F. Kotze, A. duP Heyns, M. G. Lotter, P. Wessels, and J. P. Roodt. "THE EFFECT OF INTRAVENOUS IMMUNOGLOBULIN ON PLATELET KINETICS IN CHRONIC IMMUNE THROMBOCYTOPAENIC PURPURA (ITP)." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644585.

Full text
Abstract:
Most patients with ITP respond to high doses of intravenous immunoglobulin (IVIg) with a transient increase in platelet count. The effect of IVIg on platelet kinetics was studied in 5 patients with chronic ITP. Autologous platelets were labelled with In-111 and mean platelet lifespan (MPLS) calculated; in vivo distribution and sites of platelet sequestration were determined with a scintillation camera and computer assisted image analysis. The studies were performed before and after treatment with 2 g/kg Sandoglobulin. Two groups of patients were identified: those with a splenic platelet sequestration pattern (spleen-liver In-111-activity ratio >1.4) and those with diffuse sequestration of platelets in the reticuloendothelial system (RES).There was a significant difference in mean platelet counts before and after treatment (p<0.05). Patients with a splenic sequestration pattern responded better to IVIg: the MPLS lengthened and the high spleen-liver ratio decreased. In the diffuse RES sequestration pattern group, IVIg had almost no effect on platelet kinetics. We conclude that platelet kinetic studies identify a subgroup of patients with ITP who will respond to IVIg therapy.
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Intravenous Immunoglobulin"

1

Hammer, Carrie, Howard Tyler, James A. Roth, and James D. Quigley. Characterization of Reactions to Intravenous Immunoglobulin in Neonatal Calves. Ames (Iowa): Iowa State University, January 2004. http://dx.doi.org/10.31274/ans_air-180814-837.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Ren, Xiangge, Mengmeng Zhang, Jinyu Ni, and Wensheng Zhai. Efficacy, safety and economy of different doses of intravenous immunoglobulin in the treatment of idiopathic thrombocytopenic purpura in children: A systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, July 2022. http://dx.doi.org/10.37766/inplasy2022.7.0126.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Intravenous Immunoglobulin' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography